By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has chosen Topin & Associates to help with its marketing strategy for a molecular diagnostic test to determine proper dosing for cancer drug 5-fluorouracil.

Under the terms of the deal, Topin will create a marketing strategy around the test, called OnDose, and prepare material in order to aid Myriad's sales force in selling the test to oncologists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.